NanoViricides Inc (NNVC)

AMEXHealth CareBiotechnologySnapshot 2026-10-23

$1.40+0.72%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge NanoViricides Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.11
Annual ending 2027-06-30
Revenue	—	7M
EPS	—	-0.46
Annual ending 2028-06-30
Revenue	—	76.5M
EPS	—	0.5

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Generate measurable revenue	A primary condition in NanoViricides Inc's published investment case. The stated target is Revenue > $5 million.	Broken	Revenue remains at or near zero next 4 quarters	Revenue: $0 FY2026-Q4; GAAP. Published target: Revenue > $5 million. Target period is not explicitly aligned with this observation. Source published Sep 28, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain manageable debt levels	A supporting condition in NanoViricides Inc's published investment case. The stated target is No new debt issuances beyond current agreements.	Under Pressure	New debt issuance announced within 12 months	New equity issuance (not debt) vs no new debt target No new debt issuance found. Recent capital raises were equity (common stock), not debt. Target condition (no new debt) is intact. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS loss narrows toward zero	A primary condition in NanoViricides Inc's published investment case. The stated target is EPS loss improves to better than -$0.20.	Broken	EPS loss remains worse than -$0.35 in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-06-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 1
2026-07-25	Unavailable	Unavailable	2 / 1
2026-07-26	Unavailable	Unavailable	2 / 1
2026-07-27	Unavailable	Unavailable	2 / 1
2026-07-28	Unavailable	Unavailable	2 / 1
2026-07-29	Unavailable	Unavailable	2 / 1
2026-07-30	Unavailable	Unavailable	2 / 1
2026-07-31	Unavailable	Unavailable	2 / 1
2026-08-01	Unavailable	Unavailable	2 / 1
2026-08-02	Unavailable	Unavailable	2 / 1
2026-08-03	Unavailable	Unavailable	2 / 1
2026-08-04	Unavailable	Unavailable	2 / 1
2026-08-05	Unavailable	Unavailable	2 / 1
2026-08-06	Unavailable	Unavailable	2 / 1
2026-08-07	Unavailable	Unavailable	2 / 1
2026-08-08	Unavailable	Unavailable	2 / 1
2026-08-09	Unavailable	Unavailable	2 / 1
2026-08-10	Unavailable	Unavailable	2 / 1
2026-08-12	Unavailable	Unavailable	2 / 1
2026-08-13	Unavailable	Unavailable	2 / 1
2026-08-14	Unavailable	Unavailable	2 / 1
2026-08-15	Unavailable	Unavailable	2 / 1
2026-08-16	Unavailable	Unavailable	2 / 1
2026-08-17	Unavailable	Unavailable	2 / 1
2026-08-18	Unavailable	Unavailable	2 / 1
2026-08-19	Unavailable	Unavailable	2 / 1
2026-08-20	Unavailable	Unavailable	2 / 1
2026-08-21	Unavailable	Unavailable	2 / 1
2026-08-22	Unavailable	Unavailable	2 / 1
2026-08-23	Unavailable	Unavailable	2 / 1
2026-08-24	Unavailable	Unavailable	2 / 1
2026-08-25	Unavailable	Unavailable	2 / 1
2026-08-26	Unavailable	Unavailable	2 / 1
2026-08-27	Unavailable	Unavailable	2 / 1
2026-08-28	Unavailable	Unavailable	2 / 1
2026-08-29	Unavailable	Unavailable	2 / 1
2026-08-30	Unavailable	Unavailable	2 / 1
2026-08-31	Unavailable	Unavailable	2 / 1
2026-09-01	Unavailable	Unavailable	2 / 1
2026-09-02	Unavailable	Unavailable	2 / 1
2026-09-03	Unavailable	Unavailable	2 / 1
2026-09-04	Unavailable	Unavailable	2 / 1
2026-09-05	Unavailable	Unavailable	2 / 1
2026-09-06	Unavailable	Unavailable	2 / 1
2026-09-07	Unavailable	Unavailable	2 / 1
2026-09-08	Unavailable	Unavailable	2 / 1
2026-09-09	Unavailable	Unavailable	2 / 1
2026-09-10	Unavailable	Unavailable	2 / 1
2026-09-11	Unavailable	Unavailable	2 / 1
2026-09-12	Unavailable	Unavailable	2 / 1
2026-09-13	Unavailable	Unavailable	2 / 1
2026-09-14	Unavailable	Unavailable	2 / 1
2026-09-15	Unavailable	Unavailable	2 / 1
2026-09-16	Unavailable	Unavailable	2 / 1
2026-09-17	Unavailable	Unavailable	2 / 1
2026-09-18	Unavailable	Unavailable	2 / 1
2026-09-19	Unavailable	Unavailable	2 / 1
2026-09-20	Unavailable	Unavailable	2 / 1
2026-09-21	Unavailable	Unavailable	2 / 1
2026-09-22	Unavailable	Unavailable	2 / 1
2026-09-23	Unavailable	Unavailable	2 / 1
2026-09-24	Unavailable	Unavailable	2 / 1
2026-09-25	Unavailable	Unavailable	2 / 1
2026-09-26	Unavailable	Unavailable	2 / 1
2026-09-27	Unavailable	Unavailable	2 / 1
2026-09-28	Unavailable	Unavailable	2 / 1
2026-09-29	Unavailable	Unavailable	1 / 1
2026-09-30	Unavailable	Unavailable	1 / 1
2026-10-01	Unavailable	Unavailable	1 / 1
2026-10-02	Unavailable	Unavailable	1 / 1
2026-10-03	Unavailable	Unavailable	1 / 1
2026-10-04	Unavailable	Unavailable	1 / 1
2026-10-05	Unavailable	Unavailable	1 / 1
2026-10-06	Unavailable	Unavailable	1 / 1
2026-10-07	Unavailable	Unavailable	1 / 1
2026-10-08	Unavailable	Unavailable	1 / 1
2026-10-09	Unavailable	Unavailable	1 / 1
2026-10-10	Unavailable	Unavailable	1 / 1
2026-10-11	Unavailable	Unavailable	1 / 1
2026-10-12	Unavailable	Unavailable	1 / 1
2026-10-13	Unavailable	Unavailable	1 / 1
2026-10-14	Unavailable	Unavailable	1 / 1
2026-10-15	Unavailable	Unavailable	1 / 1
2026-10-16	Unavailable	Unavailable	1 / 1
2026-10-17	Unavailable	Unavailable	1 / 1
2026-10-18	Unavailable	Unavailable	1 / 1
2026-10-19	Unavailable	Unavailable	1 / 1
2026-10-20	Unavailable	Unavailable	1 / 1
2026-10-21	Unavailable	Unavailable	1 / 1
2026-10-22	Unavailable	Unavailable	1 / 1
2026-10-23	Unavailable	Unavailable	1 / 1
2026-10-24	Unavailable	Unavailable	1 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	1	0	0
2026-06-01	1	0	0
2026-07-01	2	0	0
2026-08-01	2	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Generate measurable revenuePublished status: Broken
Maintain manageable debt levelsPublished status: Under Pressure
EPS loss narrows toward zeroPublished status: Broken

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-58.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

NanoViricides Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, speculative development-stage healthcare company, not an established earnings compounder. The long-term thesis is in a watch state: management continues to focus on NV-387, but the evidence of operating progress remains limited.

What's priced into NanoViricides Inc

The snapshot provides no valuation measure or explicit account of market expectations, so whether NNVC is cheap or expensive versus peers is unclear. The available evidence points to a company still making losses and raising capital, rather than established commercial earnings.

What the fundamentals likely do

Near term, losses and funding needs remain central: management has raised capital through offerings, while operating deficits continue despite some reduction in losses. NV-387 development is a multi-year opportunity, but the evidence gives no revenue data to gauge commercial progress; near-term results also carry elevated miss risk.

What NanoViricides Inc hinges on

The multi-year thesis hinges on progress in developing and commercializing NV-387, alongside better control of operating losses and cash burn. In the near term, continued financing needs and the direction of healthcare-sector bellwethers are key swing factors; weaker sector results could remove a current tailwind.